MA48863B1 - TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES - Google Patents
TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USESInfo
- Publication number
- MA48863B1 MA48863B1 MA48863A MA48863A MA48863B1 MA 48863 B1 MA48863 B1 MA 48863B1 MA 48863 A MA48863 A MA 48863A MA 48863 A MA48863 A MA 48863A MA 48863 B1 MA48863 B1 MA 48863B1
- Authority
- MA
- Morocco
- Prior art keywords
- tgf
- fusion proteins
- receptor type
- beta receptor
- related uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne, selon certains aspects, des polypeptides de fusion ?ßr?? Comprenant une partie hétérologue et une partie tronquée de liaison à un ligand du domaine extracellulaire du polypeptide ?ßr??, utiles pour antagoniser de manière sélective un ligand ?ßr??. L'invention concerne également des compositions et des procédés destinées à être utilisés pour traiter ou prévenir des troubles associés au tgfß.Certain aspects of the present invention relate to ?ßr?? fusion polypeptides. Comprising a heterologous portion and a truncated ligand-binding portion of the extracellular domain of the ?ßr?? polypeptide, useful for selectively antagonizing a ?ßr?? ligand. Also provided are compositions and methods for use in treating or preventing disorders associated with tgfß.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762501229P | 2017-05-04 | 2017-05-04 | |
PCT/US2018/030816 WO2018204594A1 (en) | 2017-05-04 | 2018-05-03 | Tgf-beta receptor type ii fusion proteins and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MA48863A MA48863A (en) | 2020-04-01 |
MA48863B1 true MA48863B1 (en) | 2023-08-31 |
Family
ID=88016828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA48863A MA48863B1 (en) | 2017-05-04 | 2018-05-03 | TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES |
Country Status (1)
Country | Link |
---|---|
MA (1) | MA48863B1 (en) |
-
2018
- 2018-05-03 MA MA48863A patent/MA48863B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA48863A (en) | 2020-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34802B1 (en) | NEW ANTIGEN | |
MA42622B1 (en) | LIAISONS IN TIGIT AND THEIR USES | |
EP4241848A3 (en) | Tgf-beta receptor type ii fusion proteins and uses thereof | |
MA39061A1 (en) | Aplnr modulators and their uses | |
PE20191551A1 (en) | DESIGNED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | |
MA40094B1 (en) | Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use | |
AR099079A1 (en) | FC REGIONAL VARIANTS WITH MODIFIED FCRN UNION PROPERTIES | |
WO2021041715A3 (en) | Compositions including igg fc mutations and uses thereof | |
SG10201908259WA (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits | |
PE20090359A1 (en) | POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS | |
AU2001228212A1 (en) | Beta-turn peptidomimetic cyclic compounds | |
GB201009493D0 (en) | Modified recombinant factor viii and von willebrand factor and methods of use | |
EA201201047A1 (en) | METHODS AND COMPOSITIONS IN WHICH APPLY FGF 23 POLYPEPTIDES | |
EP4324481A3 (en) | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same | |
MA44334A (en) | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST | |
NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
RU2014153099A (en) | THERAPEUTIC OR PREVENTIVE AGAINST DEMENTIA | |
MA39254B2 (en) | Aggregating and high affinity stable antibodies based on vl viral domains and vhh derivative | |
MX2010004660A (en) | NEW ANTIBODIES SPECIFIC OF THE beta-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS. | |
TW200636242A (en) | Methods of modulating the activities of α7 nicotinic acetylcholine receptor | |
BRPI0507019A (en) | composition, antibody use, antibody, msrv / herv-w env-su use | |
WO2021189010A8 (en) | Methods of using activin receptor type iib variants | |
DE602007009803D1 (en) | POLYPEPTIDES RECOGNIZED BY ANTI-TRICHINELLA ANTIBODIES AND THEIR USE | |
MX2012001278A (en) | Anti - tgf - beta receptor type ii single domain antibodies. | |
MA48863B1 (en) | TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES |